Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.

Journal of neuro-oncology - 1 Jan 2021

Gomes Isabella, Moreno Daniel Antunes, Dos Reis Mariana Bisarro, da Silva Luciane Sussuchi, Leal Letícia Ferro, Gonçalves Gisele Melo, Pereira Caio Augusto, Oliveira Marco Antônio, de Medeiros Matsushita Marcus, Reis Rui Manuel

Abstract excerpt

INTRODUCTION: Glioblastoma (GBM) is the deadliest primary brain tumor. The standard treatment consists of surgery, radiotherapy, and temozolomide (TMZ). TMZ response is heterogeneous, and MGMT promoter (MGMTp) methylation has been the major predictive biomarker. We aimed to describe the clinical and molecular data of GBMs treated with TMZ, compare MGMT methylation with MGMT expression, and further associate with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Glioblastoma

Share to Isocitrate Dehydrogenase

Share to Survival Rate

Share to Temozolomide

Source

Identifiers

PMID: 33400009
DOI: 10.1007/s11060-020-03675-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.PMID 33400009Read ↗

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.Semantic proximity Read ↗

Association of MGMT Gene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-type IDH Glioblastoma.Semantic proximity Read ↗

Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genesSemantic proximity Read ↗

TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastomaSemantic proximity Read ↗

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.Semantic proximity Read ↗

Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.Semantic proximity Read ↗

The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.Semantic proximity Read ↗

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?Semantic proximity Read ↗

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patientsSemantic proximity Read ↗

Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter StudySemantic proximity Read ↗

TERT Promoter Mutation in Adult Glioblastomas: It's Correlation with Other Relevant Molecular Markers.Semantic proximity Read ↗

Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.